SEC Info - Establishment Labs Holdings Inc.

SEC Info℠

Home

Help

Please Sign In

Establishment Labs Holdings Inc. – ‘8-K’ for 4/2/24

On: Tuesday, 4/2/24, at 11:15am ET · For: 4/2/24 · Accession #: 1688757-24-42 · File #: 1-38593

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/02/24  Establishment Labs Holdings Inc.  8-K:8       4/02/24   10:146K

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     26K 
 5: R1          Cover                                               HTML     46K 
 7: XML         IDEA XML File -- Filing Summary                      XML     12K 
10: XML         XBRL Instance -- esta-20240402_htm                   XML     15K 
 6: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- esta-20240402_lab                     XML     63K 
 4: EX-101.PRE  XBRL Presentations -- esta-20240402_pre              XML     34K 
 2: EX-101.SCH  XBRL Schema -- esta-20240402                         XSD     10K 
 8: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    17K 
 9: ZIP         XBRL Zipped Folder -- 0001688757-24-000042-xbrl      Zip     13K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

esta-20240402

i Buiding B15 and 25 i Coyol Free Zone i Alajuela i Costa Rica i NASDAQ i 506 i 24 i 34 2400 i 0001688757 i false00016887572024-04-022024-04-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


i April 2, 2024
Date of Report (date of earliest event reported)

i Establishment Labs Holdings Inc.

(Exact name of registrant as specified in its charter)

i British Virgin Islands

i 001-38593

i 98-1436377

(State or other jurisdiction of
incorporation or organization)

(Commission File No.)

(I.R.S. Employer
Identification Number)

i Buiding B15 and 25

i Coyol Free Zone

i Alajuela

i Costa Rica

(Address of principal executive offices) (Zip Code)

+506 2434 2400

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of each exchange on which registered
i Common Shares, No Par Value	i ESTA	The i NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2) of this chapter.

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On April 2, 2024, during the J.P. Morgan MedTech 2024 CEO Conference Call Series, Establishment Labs (the “Company”) is announcing that the U.S. Food and Drug Administration (the “FDA”) has scheduled the PMA preapproval inspection of the Company’s manufacturing facility for Motiva Implants. The inspection by the FDA is scheduled to take place during the second quarter of 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ESTABLISHMENT LABS HOLDINGS INC.

Dated:

April 2, 2024

By:

/s/ Rajbir S. Denhoy

Name:

Rajbir S. Denhoy

Title:

Chief Financial Officer